parecoxib has been researched along with naproxen in 4 studies
| Studies (parecoxib) | Trials (parecoxib) | Recent Studies (post-2010) (parecoxib) | Studies (naproxen) | Trials (naproxen) | Recent Studies (post-2010) (naproxen) |
|---|---|---|---|---|---|
| 436 | 186 | 229 | 4,551 | 1,057 | 1,429 |
| Protein | Taxonomy | parecoxib (IC50) | naproxen (IC50) |
|---|---|---|---|
| Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 1.1642 | |
| Hormone-sensitive lipase | Rattus norvegicus (Norway rat) | 1.2 | |
| Prostaglandin G/H synthase 1 | Homo sapiens (human) | 4.0203 | |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | 3.8725 | |
| Prostaglandin G/H synthase 2 | Rattus norvegicus (Norway rat) | 0.06 | |
| Aldo-keto reductase family 1 member C3 | Homo sapiens (human) | 0.5867 | |
| Aldo-keto reductase family 1 member C2 | Homo sapiens (human) | 1.26 | |
| Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 3.36 | |
| Solute carrier family 22 member 6 | Homo sapiens (human) | 5.8 | |
| Prostaglandin G/H synthase 1 | Rattus norvegicus (Norway rat) | 0.06 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Goldstein, JL; Harris, SI; Hubbard, RC; Kuss, M | 1 |
| Burian, M; Geisslinger, G | 1 |
| Deray, G; Montalescot, G; Sibilia, J | 1 |
| Atkinson, TJ; Fudin, J; Jahn, HL; Kubotera, N; Rennick, AL; Rhorer, M | 1 |
3 review(s) available for parecoxib and naproxen
| Article | Year |
|---|---|
[Clinical pharmacology of the selective COX-2 inhibitors].
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Clinical Trials, Phase III as Topic; Cyclooxygenase Inhibitors; Diclofenac; Humans; Isoxazoles; Lactones; Naproxen; Osteoarthritis; Pain; Pain, Postoperative; Placebos; Pyrazoles; Sulfonamides; Sulfones | 2003 |
[What do we know about the cardiovascular toxicity of the NSAIDs?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Case-Control Studies; Celecoxib; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Diclofenac; Follow-Up Studies; Humans; Isoxazoles; Lactones; Meta-Analysis as Topic; Middle Aged; Naproxen; Pyrazoles; Randomized Controlled Trials as Topic; Risk Factors; Sulfonamides; Sulfones; Thrombosis; Time Factors | 2006 |
What's new in NSAID pharmacotherapy: oral agents to injectables.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Humans; Hyaluronic Acid; Hydrogen Sulfide; Ibuprofen; Injections; Injections, Intra-Articular; Isoxazoles; Nanoparticles; Naproxen; Nitric Oxide Donors; Vasodilator Agents | 2013 |
1 trial(s) available for parecoxib and naproxen
| Article | Year |
|---|---|
Upper gastrointestinal safety evaluation of parecoxib sodium, a new parenteral cyclooxygenase-2-specific inhibitor, compared with ketorolac, naproxen, and placebo.
Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; Female; Gastric Mucosa; Humans; Infusions, Parenteral; Isoenzymes; Isoxazoles; Ketorolac; Male; Membrane Proteins; Naproxen; Peptic Ulcer; Prostaglandin-Endoperoxide Synthases | 2001 |